(Q47744182)

English

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

Antoni Berenguer-Llergo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

A Sebio

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Páez

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Salazar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

L Paré-Brunet

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

E Del Río

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Tobeña

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Martín-Richard

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Baiget

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A Barnadas

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

20 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

The Pharmacogenomics Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

256-262

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23959273%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

The ERBB network: at last, cancer therapy meets systems biology.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

An integrated encyclopedia of DNA elements in the human genome

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2013.29

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47744182&oldid=2208804860"